Treatment of malignant hypertension with sodium nitroprusside.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D003981:Diazoxide / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D005292:Ferricyanides / Q000008:administration & dosage / Q000627:therapeutic use*; D005665:Furosemide / Q000008:administration & dosage; D006145:Guanethidine / Q000008:administration & dosage; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage; D006852:Hydrochlorothiazide / Q000008:administration & dosage; D006974:Hypertension, Malignant / Q000188:drug therapy*; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage; D008875:Middle Aged; D009569:Nitric Oxide / Q000008:administration & dosage / Q000627:therapeutic use; D012110:Reserpine / Q000008:administration & dosage; D013861:Thiocyanates / Q000097:blood; D013997:Time Factors
D005292:Ferricyanides; D013861:Thiocyanates; D006852:Hydrochlorothiazide; D006830:Hydralazine; D009569:Nitric Oxide; D008750:Methyldopa; D005665:Furosemide; D012110:Reserpine; D003981:Diazoxide; D006145:Guanethidine